Related Experiment Video

Updated: Feb 11, 2026

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.6K

Rucaparib: a new treatment option for ovarian cancer

Ilaria Sabatucci1, Giuseppa Maltese1, Stefano Lepori1

  • 1a Department of Gynecologic Oncology , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.

Expert Opinion on Pharmacotherapy
|April 20, 2018
PubMed
Abstract

Insights

Rucaparib, a PARP inhibitor, shows efficacy in treating ovarian cancer by exploiting homologous recombination deficiencies. It is approved for recurrent BRCA-mutated cases and under review for maintenance therapy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • High-grade serous ovarian cancers often exhibit homologous recombination (HR) pathway deficiencies.
  • PARP inhibitors induce synthetic lethality in HR-deficient tumors by blocking DNA repair.
  • Rucaparib is a PARP inhibitor investigated for ovarian cancer treatment.

Purpose of the Study:

  • To review the efficacy and toxicity of rucaparib in ovarian cancer.
  • To evaluate rucaparib's role in the ovarian cancer treatment algorithm, including NGS Foundation Medicine insights.
  • To present future perspectives on rucaparib development.

Main Methods:

  • Review of clinical data on rucaparib efficacy and toxicity.
  • Analysis of Next-Generation Sequencing (NGS) Foundation Medicine evaluations.
  • Discussion of regulatory approvals and future therapeutic strategies.

Main Results:

  • Rucaparib is FDA-approved for recurrent BRCA-mutated ovarian cancer post-chemotherapy.
  • Supplemental new drug application accepted for maintenance use in platinum-sensitive responders.
  • EMA approval for maintenance use is pending.

Conclusions:

  • Rucaparib demonstrates significant clinical utility in specific ovarian cancer populations.
  • Maintenance therapy with rucaparib holds promise for improving patient outcomes.
  • Future research may explore rucaparib in combination therapies and earlier treatment lines.
Keywords:
BRCA mutationPARP inhibitorovarian cancerrucaparib

More Related Videos

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens05:58

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

14.2K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.2K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.0K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K